Search research articles
Contact Us
Filters
Showing results (1-10 of 178) with videos related to
Page
of 18
Sort By:
European Urology
|
April 14, 2018
Re: Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial
Marco Moschini, Paul Sargos,
European Urology
|
October 8, 2024
From a Storm to Sunshine: The Future of Bladder-sparing Therapy is Bright
Paul Sargos, Evanguelos Xylinas, Jonathan Khalifa
European Urology
|
October 24, 2025
Reply to Federico Iori, Emanuele Alì, and Cinzia Iotti's Letter to the Editor re: Nicolas Demogeot, Paul Sargos, Julia Salleron, et al. Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.07.019
Nicolas Demogeot, Stéphane Supiot, Paul Sargos
IEEE Journal of Biomedical and Health Informatics
|
September 22, 2020
Modeling Texture in Deep 3D CNN for Survival Analysis
Ahmad Chaddad, Paul Sargos, Christian Desrosiers
European Urology
|
October 24, 2025
Reply to Mattia Longoni, Giorgio Gandaglia, and Francesco Montorsi's Letter to the Editor re: Nicolas Demogeot, Paul Sargos, Julia Salleron, et al. Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.07.019
Nicolas Demogeot, Stéphane Supiot, Paul Sargos
Current Oncology Reports
|
January 25, 2023
Nectin-4: a Tumor Cell Target and Status of Inhibitor Development
Wafa Bouleftour, Paul Sargos, Nicolas Magne
European Urology Oncology
|
November 29, 2025
Re: Markus Graefen, Fabian Falkenbach, Tobias Maurer, et al. Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.09.4144
Constance Huck, Paul Sargos, Alberto Bossi
World Journal of Urology
|
May 18, 2021
Immunotherapy in genitourinary cancers: achievements and perspectives
Evanguelos Xylinas, Mathieu Roumiguié, Paul Sargos
International Journal of Radiation Oncology, Biology, Physics
|
September 6, 2025
Hypofractionated Radiation Therapy for Prostate Cancer in the Postoperative Setting: Is It Capable of Going the Distance?
Vérane Achard, Nicolas Benziane-Ouaritini, Paul Sargos
European Urology Oncology
|
February 18, 2026
Re: Riccardo Bertolo, Antonio Luigi Pastore, Paolo Verze, et al. Real-World Burden and Management of Late Genitourinary Toxicity After Prostate Radiotherapy: Insights from IRRADIaTE, the Italian Registry of Radiotherapy-Associated Disorders and Urological Treatment & Evaluation. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2026.01.005
Alfonso Gomez-Iturriaga, Paul Sargos, Piet Ost, et al.
Page
of 18
Search research articles
Search
Showing results (1-10 of 178) with videos related to
Sort By:
Page
of 18
European Urology
|
April 14, 2018
Re: Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial
Marco Moschini, Paul Sargos,
European Urology
|
October 8, 2024
From a Storm to Sunshine: The Future of Bladder-sparing Therapy is Bright
Paul Sargos, Evanguelos Xylinas, Jonathan Khalifa
European Urology
|
October 24, 2025
Reply to Federico Iori, Emanuele Alì, and Cinzia Iotti's Letter to the Editor re: Nicolas Demogeot, Paul Sargos, Julia Salleron, et al. Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.07.019
Nicolas Demogeot, Stéphane Supiot, Paul Sargos
IEEE Journal of Biomedical and Health Informatics
|
September 22, 2020
Modeling Texture in Deep 3D CNN for Survival Analysis
Ahmad Chaddad, Paul Sargos, Christian Desrosiers
European Urology
|
October 24, 2025
Reply to Mattia Longoni, Giorgio Gandaglia, and Francesco Montorsi's Letter to the Editor re: Nicolas Demogeot, Paul Sargos, Julia Salleron, et al. Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.07.019
Nicolas Demogeot, Stéphane Supiot, Paul Sargos
Current Oncology Reports
|
January 25, 2023
Nectin-4: a Tumor Cell Target and Status of Inhibitor Development
Wafa Bouleftour, Paul Sargos, Nicolas Magne
European Urology Oncology
|
November 29, 2025
Re: Markus Graefen, Fabian Falkenbach, Tobias Maurer, et al. Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.09.4144
Constance Huck, Paul Sargos, Alberto Bossi
World Journal of Urology
|
May 18, 2021
Immunotherapy in genitourinary cancers: achievements and perspectives
Evanguelos Xylinas, Mathieu Roumiguié, Paul Sargos
International Journal of Radiation Oncology, Biology, Physics
|
September 6, 2025
Hypofractionated Radiation Therapy for Prostate Cancer in the Postoperative Setting: Is It Capable of Going the Distance?
Vérane Achard, Nicolas Benziane-Ouaritini, Paul Sargos
European Urology Oncology
|
February 18, 2026
Re: Riccardo Bertolo, Antonio Luigi Pastore, Paolo Verze, et al. Real-World Burden and Management of Late Genitourinary Toxicity After Prostate Radiotherapy: Insights from IRRADIaTE, the Italian Registry of Radiotherapy-Associated Disorders and Urological Treatment & Evaluation. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2026.01.005
Alfonso Gomez-Iturriaga, Paul Sargos, Piet Ost, et al.
Page
of 18